MUMBAI, April 23 (Reuters) - Indian biotech firm Biocon Ltd has filed a prospectus for the initial public offering of its $600 million research and development arm, Syngene, it said on Thursday.
The company plans to sell 22 million shares, including an overallotment, it said in a statement, after the prospectus was filed with India's market regulator.
07:49 Murdoch's Twenty-First Century Fox Bids $14 Billion For UK's Sky10
02:11 Murdoch Pounces on Sky as Lower Pound Makes Takeover Cheaper5
19:34 CEO shift at Coca-Cola could usher in more dealmaking to refresh soda giant's growth13
16:37 Fitbit acquires software assets from rival Pebble14